A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone.

Subst Use Misuse 2018 01 19;53(2):220-229. Epub 2017 Dec 19.

o Department of Psychiatry , Washington University School of Medicine , St. Louis , Missouri , USA.

Background: Buprenorphine and naloxone (bup/nal), a combination partial mu receptor agonist and low-dose delta mu antagonist, is presently recommended and used to treat opioid-use disorder. However, a literature review revealed a paucity of research involving data from urine drug tests that looked at compliance and abstinence in one sample.

Method: Statistical analysis of data from the Comprehensive Analysis of Reported Drugs (CARD) was used to assess compliance and abstinence during treatment in a large cohort of bup/nal patients attending chemical-dependency programs from eastern USA in 2010 and 2011.

Results: Part 1: Bup/nal was present in 93.4% of first (n = 1,282; p <.0001) and 92.4% of last (n = 1,268; p <.0001) urine samples. Concomitantly, unreported illicit drugs were present in 47.7% (n = 655, p =.0261) of samples. Patients who were compliant to the bup/nal prescription were more likely than noncompliant patients to be abstinent during treatment (p =.0012; odds ratio = 1.69 with 95% confidence interval (1.210, 2.354). Part 2: An analysis of all samples collected in 2011 revealed a significant improvement in both compliance (p < 2.2 × 10) and abstinence (p < 2.2 × 10) during treatment. Conclusion/Importance: While significant use of illicit opioids during treatment with bup/nal is present, improvements in abstinence and high compliance during maintenance-assisted therapy programs may ameliorate fears of diversion in comprehensive programs. Expanded clinical datasets, the treatment modality, location, and year of sampling are important covariates, for further studies. The potential for long-term antireward effects from bup/nal use requires consideration in future investigations.

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10826084.2017.1
Publisher Site
http://dx.doi.org/10.1080/10826084.2017.1400064DOI Listing
January 2018
48 Reads

Publication Analysis

Top Keywords

comprehensive analysis
8
analysis reported
8
reported drugs
8
drugs card
8
data comprehensive
8
compliance abstinence
8
attending chemical-dependency
4
low-dose delta
4
tests looked
4
delta antagonist
4
antagonist presently
4
presently recommended
4
patients attending
4
agonist low-dose
4
chemical-dependency programs
4
combination partial
4
statistical analysis
4
bup/nal combination
4
programs eastern
4
partial receptor
4

Similar Publications